NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Roche Holding AG. (OTCQX:RHHBY) resulting from allegations that Roche may have issued materially misleading business information to the investing public.
On June 5, 2017, news outlets reported that a new study showed that adding Roche’s breast cancer drug Perjeta to the company’s older treatment Herceptin only conferred a slight benefit while more than doubling the one-year treatment cost. The study also found that the combination of Perjeta with Herceptin also had higher rates of certain side effects than Herceptin alone, including severe diarrhea. On this news, shares of Roche fell sharply during intra-day trading on June 5, 2017, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Roche investors. If you purchased shares of Roche on or before June 5, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1140.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.